Applied DNA Sciences, Inc. and the Cornell University College of Veterinary Medicine announced the signing of a sponsored research agreement for a translational research study to accelerate the development and optimization of the Company’s LineaDNA™-lipid nano particle -based veterinary vaccine platform for veterinary diseases.
Agreement Focuses on the Accelerated Development of LNP-encapsulated LineaDNA™ Vaccines to Eliminate the Use of Plasmid DNA and Reduce the Dependence on Extreme Cold Chains of Today’s mRNA Vaccines
STONY BROOK, NY and ITHACA, NY / ACCESSWIRE / September 14, 2023 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (‘Applied DNA’ or the “Company”), a leader in polymerase chain reaction (“PCR”)-based technologies, and the Cornell University College of Veterinary Medicine (“CUCVM”) today announced the signing of a sponsored research agreement (the “Agreement”) for a translational research study to accelerate the development and optimization of the Company’s LineaDNA™-lipid nano particle (LNP)-based veterinary vaccine platform (the “vaccine platform”) for veterinary diseases. CUCVM is a world-ranked U.S. university for veterinary medical education, animal medicine, and biomedical research.
The goal of the study is to accelerate the development of a unique, flexible, and cost-effective animal health vaccine platform for vaccines against infectious disease. The study expands upon the Company’s recently published white paper, Next Generation Medicines, The Therapeutic Potential of LineaDNA Delivered via Lipid Nanoparticle (LNP), and will evaluate multiple LNP formulations and methods of DNA sequence optimization to maximize the immunogenicity of Cornell-designed immunogens delivered and expressed via the Company’s vaccine platform.
The global animal vaccine market is currently valued at $12.8B in 2022, with an anticipated CAGR of 9.4% through 20301. The Company and CUCVM anticipate data from the study will support at least one animal clinical trial for health indications impacting high-value animals.
“The proven potential of nucleic acid-based vaccines in human health makes them likely candidates to have a place in animal health as well,” stated Dr. James A. Hayward, president and CEO of Applied DNA. “In prior studies we have shown that enzymatically LineaDNA vaccines are simple to manufacture, stable at room temperature, can elicit robust and protective immune responses, and are compatible with LNP-based delivery. Buoyed by these data, we have sponsored development with CUCVM to assist with vaccine platform optimization and antigen selection against several diseases affecting high-value animals.”
Dr. Diego Diel, D.V.M., M.S., PhD., Associate Professor of Virology at CUCVM’s Department of Population Medicine and Diagnostics, and the project’s principal investigator, said, “CUCVM has a long track record of excellence and leadership in veterinary disease research and innovation. This partnership with Applied DNA demonstrates our commitment to harnessing advances in vaccine science to confront zoonotic diseases to lower the potential for future pandemics.”
About Applied DNA Sciences
Applied DNA Sciences is a biotechnology company developing technologies to produce and detect deoxyribonucleic acid (“DNA”). Using PCR to enable both the production and detection of DNA, we operate in three primary business markets: (i) the manufacture of DNA for use in nucleic acid-based therapeutics; (ii) the detection of DNA in molecular diagnostics testing services; and (iii) the manufacture and detection of DNA for industrial supply chain security services.
Visit adnas.com for more information. Follow us on Twitter and LinkedIn. Join our mailing list.
The Company’s common stock is listed on NASDAQ under the ticker symbol ‘APDN,’ and its publicly traded warrants are listed on OTC under the ticker symbol ‘APPDW.’
Forward-Looking Statements
The statements made by Applied DNA in this press release may be “forward-looking” in nature within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe Applied DNA’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. Actual results could differ materially from those projected due to, its history of net losses, limited financial resources, limited market acceptance, the uncertainties inherent in research and development, future clinical data and analysis, including whether any of Applied DNA’s or its partner’s therapeutic candidates will advance further in the preclinical research or clinical trial process, including receiving clearance from the U.S. Food and Drug Administration (FDA), United State Department of Agriculture (USDA) or equivalent foreign regulatory agencies to conduct clinical trials and whether and when, if at all, they will receive final or conditional approval from the FDA, USDA or equivalent foreign regulatory agencies, the unknown outcome of any applications or requests to FDA, USDA or equivalent foreign regulatory agencies, whether results from preclinical studies will be predictive of the results of later preclinical studies and clinical trials, the unknown ability to manufacture the therapeutic grade DNA in large quantities, the fact that there has never been a commercial drug product utilizing PCR-produced DNA technology approved for therapeutic use, and various other factors detailed from time to time in Applied DNA’s SEC reports and filings, including our Annual Report on Form 10-K filed on December 14, 2022, as amended, its Quarterly Report on Form 10-Q filed on February 9, 2023,May 11, 2023, and August 10, 2023 and other reports it files with the SEC, which are available at www.sec.gov. Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date hereof or to reflect the occurrence of unanticipated events, unless otherwise required by law.
Investor Relations Contact: Sanjay M. Hurry, 917-733-5573, sanjay.hurry@adnas.com
Program Contact: Brian Viscount, 631-240-8877, brian.viscount@adnas.com
Web: www.adnas.com
Twitter: @APDN
1 - Animal Vaccines Market Size, Share & Trends Analysis Report By Product (Attenuated Live Vaccines, Recombinant Vaccines), By Animal Type (Livestock, Companion), By Route Of Administration, By Region, And Segment Forecasts, 2023 - 2030,
https://www.grandviewresearch.com/industry-analysis/veterinary-animal-vaccines-market
SOURCE: Applied DNA Sciences, Inc.
View source version on accesswire.com:
https://www.accesswire.com/783868/applied-dna-partners-with-cornell-university-college-of-veterinary-medicine-to-accelerate-development-of-veterinary-vaccine-platform-targeting-diseases-that-impact-high-value-animals
